Assembly Biosciences Financials
ASMB Stock | USD 15.04 0.32 2.17% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 3.24 | 3.4108 |
|
|
Investors should never underestimate Assembly Biosciences' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Assembly Biosciences' cash flow, debt, and profitability to make informed and accurate decisions about investing in Assembly Biosciences.
Net Income |
|
Assembly | Select Account or Indicator |
Understanding current and past Assembly Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Assembly Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Assembly Biosciences' assets may result in an increase in income on the income statement.
Please note, the presentation of Assembly Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Assembly Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Assembly Biosciences' management manipulating its earnings.
Assembly Biosciences Stock Summary
Assembly Biosciences competes with Spero Therapeutics, Achilles Therapeutics, Instil Bio, CytomX Therapeutics, and Nuvation Bio. Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus infection in the United States. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Assembly Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 70 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US0453961080 |
CUSIP | 045396108 922822101 045396207 |
Location | California; U.S.A |
Business Address | Two Tower Place, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.assemblybio.com |
Phone | 833 509 4583 |
Currency | USD - US Dollar |
Assembly Biosciences Key Financial Ratios
Return On Equity | -1.02 | ||||
Profit Margin | (2.12) % | ||||
Operating Margin | (1.43) % | ||||
Price To Sales | 4.45 X | ||||
Revenue | 7.16 M |
Assembly Biosciences Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 339.9M | 283.3M | 191.1M | 101.8M | 137.5M | 130.2M | |
Other Current Liab | 13.1M | 13.0M | 7.1M | 7.1M | 6.6M | 5.0M | |
Net Debt | (34.5M) | (49.3M) | (39.2M) | (49.0M) | (17.5M) | (18.4M) | |
Retained Earnings | (439.4M) | (501.6M) | (631.4M) | (724.5M) | (785.7M) | (746.5M) | |
Accounts Payable | 1.7M | 4.6M | 2.7M | 2.5M | 461K | 438.0K | |
Cash | 46.7M | 59.4M | 45.6M | 52.4M | 19.8M | 36.5M | |
Other Assets | 1.7M | 6.4M | 1.7M | 1.0 | 1.15 | 1.09 | |
Other Current Assets | 5.4M | 13.7M | 14.5M | 4.4M | 6.7M | 3.4M | |
Total Liab | 66.7M | 42.7M | 22.1M | 19.1M | 96.4M | 101.2M | |
Total Current Assets | 282.8M | 224.5M | 154.2M | 97.0M | 133.8M | 102.4M | |
Common Stock | 32K | 34K | 48K | 49K | 5K | 4.8K | |
Net Tangible Assets | 231.6M | 198.9M | 168.9M | 82.7M | 95.1M | 107.5M | |
Capital Surpluse | 552.8M | 712.8M | 742.4M | 807.9M | 929.1M | 975.6M | |
Other Liab | 38.9M | 33.2M | 11.5M | 2.7M | 2.5M | 2.3M | |
Net Receivables | 3.4M | 1.2M | 336K | 944K | 43K | 40.9K | |
Net Invested Capital | 273.2M | 240.6M | 168.9M | 82.7M | 41.1M | 39.0M | |
Net Working Capital | 258.3M | 200.1M | 138.1M | 80.7M | 94.6M | 124.0M | |
Capital Stock | 32K | 34K | 48K | 49K | 5K | 4.8K |
Assembly Biosciences Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 4.8M | 2.6M | 82.5M | 498K | 572.7K | 544.1K | |
Operating Income | (102.7M) | (64.8M) | (132.7M) | (94.1M) | (64.6M) | (67.9M) | |
Ebit | (102.7M) | (65.5M) | (92.4M) | (94.1M) | (64.6M) | (67.9M) | |
Research Development | 85.8M | 106.8M | 68.5M | 70.0M | 48.9M | 43.3M | |
Ebitda | (102.2M) | (64.8M) | (91.9M) | (93.6M) | (64.2M) | (67.4M) | |
Net Income | (97.6M) | (59.5M) | (129.9M) | (92.1M) | (61.2M) | (64.3M) | |
Income Tax Expense | (774K) | (2.6M) | (2.5M) | (1.0M) | 33K | 34.7K | |
Income Before Tax | (98.4M) | (62.2M) | (132.4M) | (93.1M) | (61.2M) | (64.3M) | |
Total Revenue | 14.8M | 16.0M | 79.1M | 6.3M | 7.2M | 11.2M | |
Gross Profit | 16.0M | 79.0M | 5.8M | (498K) | (41.7M) | (39.7M) | |
Cost Of Revenue | 85.8M | 101.3K | 466K | 498K | 48.9M | 51.3M | |
Tax Provision | (774K) | (741K) | (2.5M) | 0.0 | 33K | 34.7K | |
Net Interest Income | 4.3M | 2.6M | 302K | 1.0M | 2.4M | 1.6M | |
Interest Income | 4.3M | 2.6M | 302K | 1.0M | 2.4M | 1.6M |
Assembly Biosciences Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 5.3M | 12.7M | (13.8M) | 6.8M | (32.6M) | (30.9M) | |
Free Cash Flow | (85.6M) | (65.2M) | (96.5M) | (84.6M) | 22.5M | 23.6M | |
Depreciation | 494K | 691K | 466K | 498K | 450K | 251.4K | |
Other Non Cash Items | 2.8M | 7.0M | 44.7M | 3.7M | 9.2M | 6.6M | |
Capital Expenditures | 1.6M | 2.2M | 3.1M | 102K | 255K | 242.3K | |
Net Income | (97.6M) | (62.2M) | (129.9M) | (93.1M) | (61.2M) | (64.3M) | |
End Period Cash Flow | 46.7M | 59.4M | 45.6M | 52.4M | 19.8M | 36.5M | |
Change To Inventory | (601K) | (3.0M) | (7.3M) | (4.1M) | (3.7M) | (3.5M) | |
Change To Netincome | 24.3M | 28.8M | 47.4M | 10.1M | 11.6M | 15.8M | |
Investments | (48.8M) | 70.3M | 27.3M | 89.2M | 37.1M | 38.9M | |
Change Receivables | (156K) | (944K) | 2.1M | (608K) | (699.2K) | (734.2K) |
Assembly Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Assembly Biosciences's current stock value. Our valuation model uses many indicators to compare Assembly Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Assembly Biosciences competition to find correlations between indicators driving Assembly Biosciences's intrinsic value. More Info.Assembly Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Assembly Biosciences' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Assembly Biosciences' earnings, one of the primary drivers of an investment's value.Assembly Biosciences Systematic Risk
Assembly Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Assembly Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Assembly Biosciences correlated with the market. If Beta is less than 0 Assembly Biosciences generally moves in the opposite direction as compared to the market. If Assembly Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Assembly Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Assembly Biosciences is generally in the same direction as the market. If Beta > 1 Assembly Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Assembly Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Assembly Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Assembly Biosciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Assembly Biosciences November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Assembly Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Assembly Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Assembly Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Assembly Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Assembly Biosciences's daily price indicators and compare them against related drivers.
Downside Deviation | 4.55 | |||
Information Ratio | 0.0051 | |||
Maximum Drawdown | 24.8 | |||
Value At Risk | (5.34) | |||
Potential Upside | 8.49 |
Complementary Tools for Assembly Stock analysis
When running Assembly Biosciences' price analysis, check to measure Assembly Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assembly Biosciences is operating at the current time. Most of Assembly Biosciences' value examination focuses on studying past and present price action to predict the probability of Assembly Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assembly Biosciences' price. Additionally, you may evaluate how the addition of Assembly Biosciences to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |